How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

746 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Comparative bioavailability of two formulations of sibutramine. (PubMed)

Comparative bioavailability of two formulations of sibutramine. This study was conducted in order to compare the bioavailability of two capsule formulations containing 15 mg of sibutramine, N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine hydrochloride monohydrate, 84485-00-7 CAS registry number. 62 healthy subjects were enrolled in a single-center, randomized, single-dose, open-label, 2-way crossover study, with a minimum washout period of 14 days. Plasma samples were (...) collected up to 72.0 hours post-dosing. R-sibutramine, S-sibutramine, N-mono-desmethyl-sibutramine (M1) and N-di-desmethyl-sibutramine (M2) levels were determined by reverse liquid chromatography and detected by tandem mass spectrometry detection, LC/MS/MS method. Pharmacokinetic parameters used for bioequivalence assessment were the area under the concentration-time curve from time zero to time of last non-zero concentration (AUC0-t) and the maximum observed concentration (Cmax). These parameters were

2009 International journal of clinical pharmacology and therapeutics Controlled trial quality: uncertain

82. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review

not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Although orlistat, sibutramine and rimonabant are all effective at reducing weight and body mass index and, compared with placebo, are all cost-effective, both sibutramine and rimonabant have been withdrawn because of safety concerns relating to potential treatment-induced fatal adverse

2012 NIHR HTA programme

83. Antidepressants for polycystic ovary syndrome. (PubMed)

potential sources of bias.We found no studies reporting any of our primary review outcomes (depression and allied mood disorder scores, quality of life and adverse events). Only one study with 16 women was eligible for inclusion. This study compared sibutramine versus fluoxetine in women with PCOS, and reported only endocrine and metabolic outcomes. It was unclear whether the participants had psychological problems at baseline. No significant difference was found between the groups for any

Full Text available with Trip Pro

2013 Cochrane

84. Obesity

authorisation for sibutramine (Reductil ® ) because the benefits no longer outweigh the risks. This CKS topic has been updated to reflect the EMEA's decision. Recommendations regarding when to consider prescribing sibutramine as well as its prescribing information and prescriptions have been removed. Issued in January 2010. October 2008 — updated. On 23 October 2008, the EMEA's CMHP recommended the suspension of the marketing authorisation for rimonabant (Acomplia ® ) because the benefits no longer outweigh (...) the risks. This CKS topic has been updated to reflect the EMEA's decision. Recommendations regarding when to consider prescribing rimonabant as well as its prescribing information and prescriptions have been removed. Issued in November 2008. July 2008 — minor update to incorporate the recommendation from NICE that rimonabant may now be prescribed as an alternative to orlistat or sibutramine. A scenario on prescribing rimonabant has been added. May 2008 — minor update to text to reflect updated advice

2017 NICE Clinical Knowledge Summaries

85. Vagal Nerve Blockade for Obesity: VBLOC Therapy Using the Maestro RC2 Device

Apr 13]. Available from: National Heart, Lung, and Blood Institute. Aim for a healthy weight: key recommendations [Internet]. Bethesda (MD): The Institute; [2014]. [cited 2015 Apr 13]. Available from: Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev. 2009 Sep;10(5):564-75. Bray GA. Medications for weight reduction. Med Clin North Am. 2011 Sep;95(5):989-1008

2015 CADTH - Issues in Emerging Health Technologies

87. Vagal Nerve Blockade for Obesity: VBLOC Therapy Using the Maestro RC2 Device

Apr 13]. Available from: National Heart, Lung, and Blood Institute. Aim for a healthy weight: key recommendations [Internet]. Bethesda (MD): The Institute; [2014]. [cited 2015 Apr 13]. Available from: Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev. 2009 Sep;10(5):564-75. Bray GA. Medications for weight reduction. Med Clin North Am. 2011 Sep;95(5):989-1008

2015 CADTH - Issues in Emerging Health Technologies

91. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

lifestyle goals, including normal weight, were met. 279 The Sibutramine Cardiovascular Outcomes (SCOUT) trial followed up 10 000 patients with CVD or type 2 diabetes mellitus and found that even modest weight loss reduced cardiovascular mortality in the following 4 to 5 years. 280 Reduction in body weight improves control of hypertension. A meta-analysis of 25 trials showed mean SBP and DBP reductions of 4.4 and 3.6 mm Hg, respectively, with a 5.1-kg weight loss. 281 The US Preventive Services Task

2014 American Heart Association

93. Observational study: Metformin associated with better cardiovascular outcomes than other glycaemic therapies

glycaemic therapies Zachary T Bloomgarden Statistics from Altmetric.com Context A question exists as to whether the outcome of glycaemic treatment of diabetes varies with the agent used; speculation surrounds whether metformin might be preferable to other treatments. Methods Ghotbi and colleagues performed an epidemiological analysis of 8192 obese patients with diabetes at increased cardiovascular risk participating in the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Mortality and a combined (...) cardiovascular outcome of non-fatal myocardial infarction, non-fatal stroke, resuscitation after cardiac arrest or cardiovascular death were compared among those receiving one of the following interventions: no pharmacological glycaemic treatment, metformin monotherapy, insulin monotherapy, sulfonylurea monotherapy, metformin plus sulfonylurea and metformin plus insulin. Each group consisted of approximately 1000–1500 participants, randomised to either sibutramine or control (the main purpose of the trial

2014 Evidence-Based Medicine (Requires free registration)

94. Primary prevention of cardiovascular disease: new guidelines, technologies and therapies

Organisation) diet, have greater weight loss and lower attrition rates in the short term, but longer-term evidence is lacking. Weight-loss medications available to date have been disappointing because of the lack of sustained weight loss and the risk of side effects. Several weight-loss medications have been withdrawn from market due to harmful effects, the most recent being sibutramine. In addition, weight loss achieved using medication is unlikely to have the same health benefits as weight loss achieved (...) . Systematic review of randomized controlled trials of low-carbohydrate vs. low-fat/low-calorie diets in the management of obesity and its comorbidities. Obes Rev 2009; 10: 36-50. Therapeutic Goods Administration. Sibutramine (Reductil) – withdrawal in Australia. 8 Oct 2010. (accessed Feb 2013). National Health and Medical Research Council. Clinical practice guideline for the management of overweight and obesity in adults, adolescents and children in Australia. Public consultation draft — 29 March 2012

2013 MJA Clinical Guidelines

95. Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue (PubMed)

, involved in the pathogenic mechanisms underlying this syndrome. We revised the effects, and underlying mechanisms, of the current approved drugs for dyslipidemia and obesity (fibrates, statins, niacin, resins, ezetimibe, and orlistat; sibutramine; and diethylpropion, phentermine/topiramate, bupropion and naltrexone, and liraglutide) on adipose tissue. Specifically, we explored how these drugs can modulate the complex pathways involved in metabolism, inflammation, atherogenesis, insulin sensitivity

Full Text available with Trip Pro

2018 International journal of endocrinology

96. Pharmacokinetics of Simvastatin Post Laparoscopic Sleeve Gastrectomy (LSG)

, carbamazepine, rifampicin, ketoconazole, fluconazole, itraconazole, voriconanzole, diltiazem, verapamil, dexamethasone, prednisolone, phenytoin, ritonavir, indinavir, nelfinavir, bosentan, telithromycin, nefazodone, St John's wort, orlistat, sibutramine and other strong CYP 3A4 inhibitors/ inducers Pregnant ladies Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2018 Clinical Trials

97. Enzyme Kinetics and Molecular Docking Studies on Cytochrome 2B6, 2C19, 2E1, and 3A4 Activities by Sauchinone (PubMed)

key amino acid residues in the active site of CYP2B6, 2C19, 2E1, and 3A4. When sibutramine, clopidogrel, or chlorzoxazone was co-administered with sauchinone to mice, the systemic exposure of each drug was increased compared to that without sauchinone, because sauchinone reduced the metabolic clearance of each drug. In conclusion, when sauchinone was co-treated with drugs metabolized via CYP2B6, 2C19, 2E1, or 3A4, sauchinone-drug interactions occurred because sauchinone inhibited the CYP-mediated

Full Text available with Trip Pro

2018 Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry

98. Idebenone Treatment of Early Parkinson's Diseasesymptoms

) Exclusion Criteria: (1)Patients with disturbance of consciousness, aphasia and mental illness; patients with major depression (HAD scale score ≥ 15 points) (2)Patients with Parkinson's superimposition syndrome and patients with secondary Parkinson's syndrome (hepatolenticular degeneration, hepatic encephalopathy, cerebellar disease, hydrocephalus, parathyroid disease, etc.) (3)Patients who have long-term use of dopamine blockers (such as potent neuroleptics, sibutramine, reserpine, metoclopramide, etc

2018 Clinical Trials

99. Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

(phentermine, sibutramine, orlistat) or lipid dissolving injections within 3 months. Over 3 days of treatment with oral or parenteral corticosteroids within 2 weeks of the screening visit. Recent history (within 2 years prior to the screening visit) of alcohol or drug abuse. Significant change in smoking habits within 3 months prior to screening. Participated in any clinical study with an investigational drug, biologic, or device within 3 month prior to screening. Significant change in diet or level

2018 Clinical Trials

100. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials

that anti-obesity therapy was associated with weight loss regardless of the drug used. Orlistat and rimonabant may be associated with cardiovascular risk factor improvements, but sibutramine may contribute to increased incidence of cardiovascular events. Given the unknown risk for publication bias, missing detail on placebo treatments and limited quality assessment, these conclusions should be interpreted cautiously. Authors' objectives To assess the effects of anti-obesity drugs on cardiovascular risk (...) . Sibutramine (5mg to 15mg daily) and rimonabant (5mg to 20mg daily) were also investigated. Details of placebo treatments were not reported. Two reviewers independently selected studies for inclusion with disagreements being discussed with a third reviewer until consensus was reached. Assessment of study quality Two reviewers independently used the Jadad scale to assess trial quality based on randomisation, allocation concealment, blinding, completeness of follow-up, and use of intention-to-treat analysis

Full Text available with Trip Pro

2012 DARE.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>